Session Abstract – PMWC 2023 Silicon Valley

Showcase Track S1 - January 25 9.00 A.M.-9.45 A.M.,Showcase Track S1 - January 26 10.00 A.M.-10.15 A.M.,Showcase Track S1 - January 27 1.15 P.M.-1.30 P.M.

The PMWC 2023 Genomic Profiling Showcase will provide a 15 min speaking opportunity for selected companies working with the latest technologies in nucleic acid sequencing such as NGS, providing instrumentation for genomic sequencing, and offering direct to consumer services. These companies will share their innovative products and services to an audience of leading investors, potential clients and partners. The Genomic Profiling Showcase will exhibit the latest innovations in methods and instruments used for DNA/ RNA sequencing to ascertain the genomic and transcriptional profile of a person in order to understand why some people get certain diseases while others do not, or why people react in different ways to the same drug. This information is also being used to develop new ways to diagnose, treat, and prevent diseases, such as cancer.

Confirmed Presenting Companies:

 Session Chair Profile

Ph.D., Chief Operating Officer, Pacific Biosciences

Mark recently joined PacBio where he will manage our research, development and manufacturing organizations and will be responsible for driving our strategic planning and corporate development activities. Mark joins the company from Illumina, Inc. where he most recently served as Senior Vice President and Chief Commercial Officer. In that role, he was responsible for the development and implementation of lllumina’s commercial strategy and oversaw worldwide sales and services of over $3B in annual revenue and ~1,800 commercial employees. Prior to Illumina, Mark was the Director of Genotyping Services for Ellipsis Biotherapeutics. He earned as B.S. in Biochemistry from Western University and was a Ph.D. candidate at the University of Toronto in the department of Molecular and Medical Genetics. During that time, his research was focused on Cystic Fibrosis at the Hospital for Sick Children in Toronto.

Genomic Profiling Showcase:
Pacific Biosciences

PacBio Systems are powered by Single Molecule, Real-Time Sequencing and provide comprehensive views of genomes, transcriptomes, and epigenomes. As the only sequencing technology to offer highly accurate long reads (HiFi reads), PacBio provides unparalleled access to the full spectrum of genetic variation in any organism

 Speaker Profile

PHD, VP & Chief Scientific Officer, PerkinElmer Genomics

Dr. Madhuri Hegde is a medical geneticist, a board certified diplomat in clinical molecular genetics by the American Board of Medical Genetics, and an ACMG Fellow. Previously, she was the Executive Director of Emory Genetics Laboratory. She received a B.Sc. and M.Sc. from the University of Bombay and a Ph.D. from the University of Auckland. She completed post-doctoral studies at Baylor College of Medicine.

Genomic Profiling Showcase:
PerkinElmer Genomics

PerkinElmer Genomics is a global leader in genetic and genomic testing focused on rare diseases, newborn screening, and inherited cancer. Using a simple saliva or blood sample, we answer complex genetic questions that can proactively inform patient care and end the diagnostic odyssey for families.

Advances in Molecular Diagnosis of Critically Ill Patients with C
Using whole genome sequencing can lead to care changes, changes in reproductive decision-making, and better resource utilization.

 Speaker Profile

PHD, CEO/CSO, Phase Genomics, Inc.

Leads Phase Genomics in both executive and technical roles.

Genomic Profiling Showcase:
Phase Genomics, Inc.

Phase Genomics applies proprietary proximity ligation technology to enable chromosome-scale genome assembly, metagenomic deconvolution, as well as analysis of structural genomic variation and genome architecture.

High-Resolution Cytogenomics Using Proximity Ligation Sequencing
Our new OncoTerra platform enables comprehensive detection of chromosomal aberrations in diverse samples, including FFPE.

 Speaker Profile

M.D., MPH, FACP, Sr. VP & Global Head of Enterprise Oncology, Labcorp

Dr. Reddy has played an integral role in advancing oncology efforts at Labcorp dedicated to advancing precision oncology to improve patient outcomes. Since joining Labcorp, he oversaw the acquisitions of OmniSeq and PGDx expanding Labcorp’s leading oncology portfolio of NGS-based genomic profiling capabilities. He previously served as VP of Medical Affairs at Foundation Medicine. He is triple board-certified in internal medicine, medical oncology, and hematology. Dr. Reddy earned his medical degree from the University of Kansas Medical Center, where he completed his internal medicine residency and clinical hematology/oncology fellowship. He obtained a master’s degree in public health (MPH) through a NIH Clinical Research Curriculum Award (K30) program and is an alumnus of Harvard Business School. Additionally, he is a fellow of the American College of Physicians. Dr. Reddy is a Lt. Col. in the U.S. Air Force Reserve, with over 17 years of service.

Genomic Profiling Showcase:

Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and lives.

Personalized Clinical Decision Support Leveraging Data Driven Ins
Harnessing technologies, increasing therapeutics access, and extracting data insights to improve outcomes and reduce healthcare costs.